US 12,215,103 B2
Fused imidazole derivative, preparation method therefor, and medical use thereof
Fanglong Yang, Shanghai (CN); Ling Zhang, Shanghai (CN); Liangliang Zheng, Shanghai (CN); Feng He, Shanghai (CN); and Weikang Tao, Shanghai (CN)
Assigned to Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu (CN)
Filed by Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu (CN)
Filed on Mar. 21, 2024, as Appl. No. 18/612,631.
Application 18/612,631 is a continuation of application No. 18/043,508, previously published as PCT/CN2021/115915, filed on Sep. 1, 2021.
Claims priority of application No. 202010905693.4 (CN), filed on Sep. 1, 2020; application No. 202010984336.1 (CN), filed on Sep. 18, 2020; application No. 202011124085.6 (CN), filed on Oct. 20, 2020; application No. 202011253077.1 (CN), filed on Nov. 11, 2020; application No. 202011407911.8 (CN), filed on Dec. 4, 2020; and application No. 202011627733.X (CN), filed on Dec. 31, 2020.
Prior Publication US 2024/0246958 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/14 (2006.01); A61P 1/16 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 495/04 (2006.01)
CPC C07D 417/14 (2013.01) [A61P 1/16 (2018.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01)] 8 Claims
 
1. A compound, wherein the compound is selected from the group consisting of:

OG Complex Work Unit Chemistry
or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof.